Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios


suck pdf from google scholar
unlimited free pdf from europmc32330343    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32330343  :  Publisher
PDF vom PMID32330343

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • COVID-19 in solid organ transplant recipients: Initial report from the US epicenter #MMPMID32330343
  • Pereira MR; Mohan S; Cohen DJ; Husain SA; Dube GK; Ratner LE; Arcasoy S; Aversa MM; Benvenuto LJ; Dadhania DM; Kapur S; Dove LM; Brown RS Jr; Rosenblatt RE; Samstein B; Uriel N; Farr MA; Satlin M; Small CB; Walsh TJ; Kodiyanplakkal RP; Miko BA; Aaron JG; Tsapepas DS; Emond JC; Verna EC
  • Am J Transplant 2020[Jul]; 20 (7): 1800-1808 PMID32330343show ga
  • Solid organ transplant recipients may be at a high risk for SARS-CoV-2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV-2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). Ninety patients were analyzed with a median age of 57 years. Forty-six were kidney recipients, 17 lung, 13 liver, 9 heart, and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%), and dyspnea (43%). Twenty-two (24%) had mild, 41 (46%) moderate, and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab, and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients.
  • |*Transplant Recipients[MESH]
  • |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH]
  • |Adult[MESH]
  • |Aged[MESH]
  • |Alanine/analogs & derivatives/therapeutic use[MESH]
  • |Antibodies, Monoclonal, Humanized/therapeutic use[MESH]
  • |Antiviral Agents/therapeutic use[MESH]
  • |Azithromycin/therapeutic use[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*complications/drug therapy/*epidemiology/mortality[MESH]
  • |Critical Care[MESH]
  • |Female[MESH]
  • |Hospitalization[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/therapeutic use[MESH]
  • |Immunosuppression[MESH]
  • |Immunosuppressive Agents/therapeutic use[MESH]
  • |Intensive Care Units[MESH]
  • |Intubation[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |New York City/epidemiology[MESH]
  • |Organ Transplantation/*adverse effects[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*complications/*epidemiology/mortality[MESH]
  • |Respiration, Artificial[MESH]
  • |SARS-CoV-2[MESH]
  • |Steroids/therapeutic use[MESH]
  • |Treatment Outcome[MESH]
  • |United States[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1800 7.20 2020